Month: October 2026

• Keynote/plenary session and late-breaking poster presentation highlight additional data from Phase 2 AMPLIFY-7P trial of camupepimut (ELI-002 7P) in KRAS-mutated pancreatic cancer
• Additional preclinical poster presentation showcases an expanded application of the AMP-platform in an antigen-agnostic intratumoral treatment approach

BOSTON, Oct. 29, 2026 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that the Company will conduct a keynote/plenary presentation, as well as two poster presentations showcasing additional results from the randomized Phase 2 AMPLIFY-7P study of camupepimut (ELI-002 7P) and an expanded antigen-agnostic intratumoral application of the AMP-adjuvant platform at the Society for Immunotherapy of Cancer’s (“SITC”) Annual Meeting. The meeting will take place November 4-8, 2026 in Phoenix, Arizona.

Presentation Details:

Keynote/Plenary Session

Title: Updates on Clinical Results from the AMPLIFY-7P Study of a Lymph Node-Targeted KRAS Vaccine
Presenter: Darrell J. Irvine, PhD, The Scripps Research Institute
Session Number/Name: 103: Thomas Waldmann Memorial Plenary Session: Cancer Vaccines, Current and Future
Presentation Date/Time: Friday, November 6, 2026, at 10:04 am MT
Location: Phoenix Convention Center – North Building – 300 Level – Halls BC

Late-Breaking Abstract Poster Presentation

Title: Seven valent mKRAS lymph node targeted amphiphile vaccine drives mKRAS-specific T cell responses that correlate with improved clinical outcomes in the AMPLIFY-7P randomized phase 2 trial
Presenter: Christopher M. Haqq
Abstract Number: 1186
Session Date/Time: Saturday, November 7, 2026, 12:30-1:30 pm MT and 6:40-8:10 pm MT
Location: Phoenix Convention Center – North Building -Lower Level – Exhibition Halls 4-6

Poster Presentation

Title: Direct intratumoral delivery of amphiphilic immunomodulators induces durable anti-tumor efficacy
Presenter: Martin Steinbuck
Abstract Number: 824
Session Date/Time: Saturday, November 7, 2026, at 12:30-1:30pm MT and 6:40-8:10pm MT
Location: Phoenix Convention Center – North Building – Lower Level – Exhibition Halls 4-6

About the AMPLIFY-7P Phase 2 Study

AMPLIFY-7P Phase 2 is a randomized study evaluating camupepimut (ELI-002 7P) versus observation in patients with mutant KRAS-driven pancreatic ductal adenocarcinoma following completion of standard locoregional therapy. The study enrolled 144 patients across 24 U.S. clinical sites.

About camupepimut (ELI-002 7P)

Camupepimut is an investigational, off-the-shelf immunotherapy designed to generate immune responses against seven of the most common KRAS mutations. Camupepimut utilizes Elicio’s proprietary Amphiphile (“AMP”) technology to target mutant KRAS peptide antigens and an immune-stimulatory adjuvant directly to the lymph nodes, where adaptive immune responses are orchestrated.

About Elicio Therapeutics

Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing next-generation immunotherapies for the treatment of KRAS-driven cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical findings in the personalized cancer immunotherapy space to develop effective, off-the-shelf immunotherapies.

Elicio’s AMP technology aims to enhance the education, activation and amplification of cancer-specific T cells relative to conventional immunotherapy strategies, with the goal of promoting durable cancer immunosurveillance in patients. Elicio’s camupepimut lead program is an off-the-shelf immunotherapy candidate targeting the most common KRAS mutations, which drive approximately 25% of all solid tumors.

Off-the-shelf immunotherapy approaches have the potential benefits of low cost, rapid, commercial-scale manufacturing and rapid availability of drug to patients, especially in neoadjuvant settings and for prophylaxis in high-risk patients, contrary to personalized immunotherapy approaches.

Elicio’s pipeline includes additional off-the-shelf therapeutic cancer immunotherapy candidates, including ELI-007 and ELI-008, which target BRAF-driven cancers and p53 hotspot mutations, respectively.

For more information, please visit www.elicio.com.

Cautionary Note on Forward-Looking Statements

Certain statements contained in this communication regarding matters that are not historical facts are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA.

These include statements regarding the timing and content of Elicio’s presentation at SITC 2026 Annual Meeting; the clinical activity, therapeutic potential and potential benefits of camupepimut (ELI-002 7P); the interpretation and potential implications of results and analyses from Elicio’s preclinical studies; the interpretation and potential implications of results and analyses from Elicio’s AMPLIFY-7P study, including the observation that mKRAS-specific T cell responses correlate with improved clinical outcomes; Elicio’s planned clinical programs, including planned clinical trials; the potential of Elicio’s product candidates and platform; the potential for pre-specified analyses to further characterize the clinical activity of camupepimut (ELI-002 7P); the potential benefits and effectiveness of off-the-shelf immunotherapy approaches; the potential participation and presentation at upcoming conferences and medical meetings; and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future and, therefore, you are cautioned not to place undue reliance on them.

No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Elicio undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law.

Elicio uses words such as “anticipates,” “believes,” “plans,” “expects,” “projects,” “future,” “intends,” “may,” “will,” “should,” “could,” “estimates,” “predicts,” “potential,” “continue,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA.

Such forward-looking statements are based on Elicio’s expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, Elicio’s plans to develop and commercialize its product candidates, including camupepimut; the timing of initiation of Elicio’s planned clinical trials; the timing of the availability and presentation of data from Elicio’s clinical trials; the design and timing of future clinical trials; the timing of any planned investigational new drug application or new drug application; Elicio’s plans to research, develop and commercialize its current and future product candidates; and Elicio’s estimates regarding future revenue, expenses, capital requirements and need for additional financing. New factors emerge from time to time, and it is not possible for Elicio to predict all such factors, nor can Elicio assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

These risks are more fully discussed under the heading “Risk Factors” in Elicio’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on March 12, 2026, as amended on April 29, 2026, Elicio’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the SEC on May 11, 2026, and Elicio’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 13, 2026, as updated by subsequent reports and other documents filed from time to time with the SEC.

Forward-looking statements included in this release are based on information available to Elicio as of the date of this release. Elicio does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this release, except to the extent required by law.

Elicio Investor Relations Contact

Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com

Always-on neuromorphic AI with on-chip learning comes to the world’s most popular single-board computer

LAGUNA HILLS, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) — BrainChip Holdings Ltd (ASX: BRN, OTCQX: BRCHF, ADR: BCHPY), a global leader in ultra-low-power, fully digital, event-based neuromorphic AI, today launched the AKD1500 Raspberry Pi 5 Development Kit. The kit pairs a Raspberry Pi 5 with BrainChip’s AKD1500 M.2 board, giving the millions of engineers, makers and product teams who already build on Raspberry Pi an off-the-shelf way to develop low-power, always-on AI applications – and a clear path to production on the same AKD1500 chip.

“As an American Tier 1 for physical AI, Hellbender looks for edge technologies that can move cleanly from prototype to production,” said Brian Beyer, CEO, Hellbender. “BrainChip’s AKD1500 Raspberry Pi 5 kit makes it easy for engineering teams to evaluate low-power, always-on AI on familiar hardware, and we see it as a promising option for the robotics and vision applications our customers are building.”

The challenge: always-on AI strains power, privacy and the path to production

A growing class of edge devices – sensors, monitors, wearables, industrial equipment and smart home products – must listen, watch or measure continuously. Running AI on these devices with conventional processors means analyzing every frame and sample, whether anything has changed, which drains batteries and adds heat. Sending the data to the cloud instead adds latency, bandwidth cost and privacy risk. And once a model is deployed, teaching it something new typically means collecting data, retraining in the cloud and pushing an update.

Developers face a second hurdle: the hardware used to build a proof of concept is often not the hardware that ships. Moving from a prototype to a production design can mean re-porting models, re-validating performance and starting over on a new platform.

The solution: event-based AI that learns on the device

AKD1500 uses BrainChip’s event-based, neuromorphic architecture to process only meaningful events rather than every piece of incoming data, making it well suited to power always-on workloads such as sensing, monitoring and detection. All processing happens on the device, so applications avoid the latency, bandwidth cost and privacy exposure of the cloud.

AKD1500 also supports on-chip learning, so models can learn new classes directly on the device without cloud retraining. A developer can teach a Raspberry Pi 5 application to recognize a new keyword, gesture or object in the field, and the data stays local.

“Raspberry Pi is where many edge AI products begin,” said Steve Brightfield, chief product officer, BrainChip. “This kit puts neuromorphic AI where developers already work and gives teams a fast, low-cost way to validate applications on streaming data.”

“Kit support will include Docker images that can be preloaded to simplify benchmarking and demos and that serve as a reference for custom neuromorphic application containers. Developers who already have a Raspberry Pi 5 with an M.2 HAT can add the production AKD1500 M.2 card and use the same software.”

From prototype to production on one chip

The kit is off the shelf and quick to set up. Teams evaluate their application on Raspberry Pi 5, then design the same AKD1500 chip into their own product with a PCIe or SPI interface to suit their system without switching to new silicon. The kit joins the AKD1500 PCIe card and AKD1500 M.2 board in BrainChip’s family of AKD1500 development platforms, and teams can prototype on any of them.

For developers, the kit offers:

• A familiar platform: Build and test edge AI on Raspberry Pi 5 hardware and workflows developers already know.
• Always-on efficiency: Event-based processing handles continuous sensing workloads without processing every input.
• Local learning and privacy: Add new keywords, gestures or objects on the device, with no cloud retraining and no data leaving the device.
• Free tools and models: BrainChip’s MetaTF software tools and models are available at no charge through the BrainChip Developer Hub.
• One chip, prototype to product: The AKD1500 chip that runs on the kit is the same one teams design into production.

Strategic significance for BrainChip

According to MarketsandMarkets, the global edge computing market is projected to grow from $111.34 billion in 2026 to $317.39 billion by 2031, fueled by organizations prioritizing faster data processing, low-latency applications and decentralized digital infrastructure.

The AKD1500 Raspberry Pi 5 Development Kit reflects BrainChip’s commitment to executing its product roadmap and delivering the production-ready tools developers need today. It advances three priorities:

• Broader developer adoption: Putting Akida in front of the Raspberry Pi community expands the pipeline of engineers who design with Akida.
• AKD1500 commercialization: Alongside the PCIe card and M.2 board, the kit completes an accessible lineup built on one chip, covering prototyping through production and creating a direct path from evaluation to chip design-ins.
• Edge AI leadership: AKD1500 brings BrainChip’s event-based processing and on-chip learning to a mainstream developer platform.

Availability

The AKD1500 Raspberry Pi 5 Development Kit is available now through the BrainChip Shop. MetaTF software tools and models are available at no charge through the BrainChip Developer Hub.

About BrainChip Holdings Ltd.

BrainChip is the worldwide leader in edge AI on-chip processing and learning. The company’s first-to-market, fully digital, event-based AI processor, Akida™, uses neuromorphic principles to analyze only essential sensor inputs at the point of acquisition, processing data with unmatched efficiency, precision and energy economy. BrainChip’s Sequora™ is an efficient digital AI processor for GenAI and other large models using state-space architectures. BrainChip’s technology is deployed across industries including aerospace, defense, industrial IoT, healthcare, consumer devices, and wearables. Explore more at www.brainchip.com.

Follow BrainChip:

X: https://www.twitter.com/BrainChip_inc

LinkedIn: https://www.linkedin.com/company/7792006

Investor Contact

IR@brainchip.com

Media Contact

Maddie Coe

PRforBrainchip@bospar.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7574c999-bb99-4b7c-881d-77f6488b0a75

MINNEAPOLIS, Oct. 29, 2026 (GLOBE NEWSWIRE) — Nortech Systems Incorporated (Nasdaq: NSYS), a leading provider of engineering and manufacturing solutions for complex electromedical and electromechanical products serving the medical imaging, medical device, aerospace & defense and industrial markets, will hold a live conference call and webcast at 3:30 p.m. Central Time on Thursday, November 12, 2026, to discuss the Company’s third quarter 2026 financial results. The call will be hosted by Jay D. Miller, Chief Executive Officer and President, and Andrew D. C. LaFrence, Chief Financial Officer. To access the live audio conference call, US participants may call 888-506-0062 and international participants may call 973-528-0011. Participant Access Code: 124682. Participants may also access the call via webcast at: https://www.webcaster5.com/Webcast/Page/2814/54544.

###

About Nortech Systems Incorporated 

Nortech Systems Incorporated (“Nortech”) is a leading provider of design and manufacturing solutions for complex electromedical devices, electromechanical systems, assemblies, and components. Nortech primarily serves the medical device, medical imaging, aerospace & defense, and industrial markets. Its design services span concept development to commercial design, and include medical device, software, electrical, mechanical, and biomedical engineering. Its manufacturing and supply chain capabilities are vertically integrated around wire/cable/interconnect assemblies, printed circuit board assemblies, as well as system-level assembly, integration, and final test. Headquartered in Maple Grove, MN, Nortech currently has six manufacturing locations and design centers across the U.S., Latin America, and Asia. Nortech is traded on the NASDAQ Stock Market under the symbol NSYS. Nortech’s website is www.nortechsys.com.

Contact
Andrew D. C. LaFrence
Chief Financial Officer and Senior Vice President of Finance
alafrence@nortechsys.com
952-345-2243

NASHVILLE, Tenn., Oct. 29, 2026 (GLOBE NEWSWIRE) — Truxton Corporation, the parent company of Truxton Trust Company (“Truxton” or “the Bank”) and its subsidiaries, announced its operating results for the quarter ended September 30, 2026. Third-quarter net income attributable to common shareholders was $7.86 million, or $0.68 per diluted share, compared to $5.63 million, or $0.49 per diluted share, for the same quarter in 2025. Truxton completed a 4-for-1 stock split on August 28, 2026. Accordingly, all share and per share data in current and comparable periods have been adjusted to reflect the split.

Key Highlights

• Non-interest income was $7.1 million in the third quarter of 2026, which was $395 thousand higher than the second quarter of 2026 and $1.08 million higher than the third quarter of 2025. Wealth revenue in the third quarter of 2026 was $6.6 million, up 6% from $6.2 million in the prior quarter and up 17% from $5.6 million in the same period in the prior year.
• Net interest income, pre-provision, was $10.1 million in the third quarter and second quarter of 2026 and was up 15% from $8.8 million in the third quarter of 2025.
• The purchase of a renewable energy tax credit for the 2022, 2023 and 2025 tax years benefited net income by approximately $645 thousand in the quarter ended September 30, 2026, by lowering tax expense.
• Loans decreased 1% to $799 million at quarter end compared to $804 million at June 30, 2026, and were up 11% compared to $720 million at September 30, 2025. Quarterly average loan balances were $803 million for the third quarter and second quarter of 2026 and up 14% from $704 million in the third quarter of 2025.
• Total deposits remained the same from June 30, 2026 to September 30, 2026 at $1.12 billion, and were 3% lower in comparison to $1.16 billion at September 30, 2025. This decline was caused by a decrease of $81 million in wholesale deposits from September 30, 2025 to September 30, 2026.
• Net interest margin for the third quarter of 2026 was 3.13%, an increase of 3 basis points from the 3.10% experienced in the quarter ended June 30, 2026, and an increase of 31 basis points from the 2.82% recorded in the quarter ended September 30, 2025. Cost of funds was 2.79% in the third quarter of 2026, up from 2.76% for the quarter ended June 30, 2026, and down from 3.08% for the quarter ended September 30, 2025.
• Asset quality remains sound at Truxton. The Bank had $96 thousand of non-performing assets at September 30, 2026, compared to $141 thousand at June 30, 2026, and $97 thousand at September 30, 2025.
• Allowance for credit losses on loans, excluding that for unfunded commitments, was $7.3 million at quarter end September 30, 2026, compared to $7.4 million at June 30, 2026, and $7.0 million at September 30, 2025. For those three periods, such allowance amounts were 0.92%, 0.92%, and 0.98% of gross loans outstanding at the respective period end. For the same three periods, the Bank’s allowance for unfunded commitments was $797 thousand, $814 thousand, and $650 thousand, respectively.
• The Bank’s capital position remains strong. Its Tier 1 leverage ratio was 9.66% at September 30, 2026, compared to 9.27% at June 30, 2026, and 8.90% at September 30, 2025. Book value per common share was $10.62, $10.78, and $9.63 at September 30, 2026, June 30, 2026, and September 30, 2025, respectively.
• During the three months ended September 30, 2026, Truxton Corporation paid dividends of $0.22 per common share, and repurchased 20,324 shares of its common stock for $519 thousand in the aggregate, or an average price of $25.51 per share.

About Truxton
Truxton is a premier provider of wealth, banking, and family office services for wealthy individuals, their families, and their business interests. Serving clients across the world, Truxton’s vastly experienced team of professionals provides customized solutions to its clients’ complex financial needs. Founded in 2004 in Nashville, Tennessee, Truxton upholds its original guiding principle: do the right thing. Truxton Trust Company is a subsidiary of financial holding company, Truxton Corporation (OTCID: TRUX). For more information, visit truxtontrust.com.

Investor Relations Austin Branstetter 615-250-0783 austin.branstetter@truxtontrust.com

Media Relations Swan Burrus 615-250-0773 swan.burrus@truxtontrust.com

Truxton Corporation
Consolidated Balance Sheets
(000’s)
(Unaudited)
		September 30, 2026*			June 30, 2026*			September 30, 2025*
ASSETS
Cash and due from financial institutions		$	5,407		$	5,269		$	4,597
Restricted cash			1,270			400			880
Interest-bearing deposits in other financial institutions			4,031			10,961			12,790
Federal funds sold			1,508			1,500			4,369
Cash and cash equivalents			12,216			18,130			22,636
Available-for-sale securities			485,648			492,163			529,752
Allowance for credit losses on securities			(342	)		(342	)		–
Available-for-sale securities, net			485,306			491,821			529,752
Loans			798,585			803,705			719,842
Allowance for credit losses on loans			(7,323	)		(7,386	)		(7,035	)
Net loans			791,262			796,319			712,807
Bank owned life insurance			17,777			17,619			17,158
Restricted equity securities			6,097			5,994			3,144
Premises and equipment, net			2,525			2,664			3,005
Accrued interest receivable			5,963			5,967			6,035
Deferred tax asset, net			6,822			3,915			4,187
Other assets			22,487			23,990			14,325
Total assets		$	1,350,455		$	1,366,419		$	1,313,049
LIABILITIES AND SHAREHOLDERS’ EQUITY
Deposits
Noninterest-bearing		$	134,705		$	143,625		$	134,017
Interest-bearing			986,455			980,520			1,024,696
Total deposits			1,121,160			1,124,145			1,158,713
Federal funds purchased			2,300			–			–
Federal Home Loan Bank advances			88,000			86,000			31,000
Federal Reserve Bank borrowings			–			16,000			–
Other liabilities			16,476			15,739			12,539
Total liabilities			1,227,936			1,241,884			1,202,252
Shareholders’ equity
Common stock, $0.10 par value			1,153			287			284
Additional paid-in capital			28,760			29,716			29,217
Retained earnings			106,483			101,158			88,524
Accumulated other comprehensive loss			(13,877	)		(6,626	)		(7,228	)
Total shareholders’ equity			122,519			124,535			110,797
Total liabilities and shareholders’ equity		$	1,350,455		$	1,366,419		$	1,313,049
*The information is preliminary, unaudited and based on company data available at the time of presentation.

Truxton Corporation
Consolidated Statements of Net Income
(000’s)
(Unaudited)
		Three Months Ended									Year To Date
		September 30, 2026*			June 30, 2026*			September 30, 2025*			September 30, 2026*			September 30, 2025*
Noninterest income
Wealth management services		$	6,564		$	6,219		$	5,631		$	18,794		$	16,177
Advisory services			42			57			15			114			1,029
Service charges on deposit accounts			89			85			88			265			251
Bank owned life insurance income			157			155			149			464			436
Other			244			185			133			541			645
Total noninterest income			7,096			6,701			6,016			20,178			18,538
Interest income
Loans, including fees			12,664			12,346			11,312			37,463			32,572
Taxable securities			5,291			5,400			5,710			16,218			14,389
Tax-exempt securities			614			607			518			1,816			1,077
Interest-bearing deposits in other financial institutions			181			252			513			637			1,159
Federal funds sold			46			41			41			143			99
Total interest income			18,796			18,646			18,094			56,277			49,296
Interest expense
Deposits			7,868			7,924			8,710			23,733			23,028
Subordinated debentures and other			–			–			189			–			565
Short-term borrowings			71			28			20			108			188
Long-term borrowings			740			632			392			1,838			1,024
Total interest expense			8,679			8,584			9,311			25,679			24,805
Net interest income			10,117			10,062			8,783			30,598			24,491
Provision for credit losses on available-for-sale securities			–			(278	)		–			(278	)		–
Provision for credit losses on loans			(80	)		201			266			(35	)		776
Net interest income after provision for credit losses			10,197			10,139			8,517			30,911			23,715
Total revenue, net			17,293			16,840			14,533			51,089			42,253
Noninterest expense
Compensation and employee benefits			6,196			5,546			5,121			17,619			15,821
Occupancy			341			362			325			1,040			1,012
Furniture and equipment			107			108			107			322			322
Data processing			409			608			519			1,611			1,341
Wealth management processing fees			192			211			211			616			640
Advertising and public relations			46			48			38			135			170
Professional services			248			271			361			756			889
FDIC insurance assessments			225			465			274			1,045			532
Other			557			614			537			1,776			1,439
Total noninterest expense			8,321			8,233			7,493			24,920			22,166
Income before income taxes			8,972			8,607			7,040			26,169			20,087
Income tax expense			1,109			1,731			1,411			4,632			4,086
Net income		$	7,863		$	6,876		$	5,629		$	21,537		$	16,001
Earnings per share**:
Basic		$	0.68		$	0.60		$	0.49		$	1.87		$	1.44
Diluted		$	0.68		$	0.59		$	0.49		$	1.87		$	1.44
*The information is preliminary, unaudited and based on company data available at the time of presentation. **Historical earnings per share is adjusted retrospectively to reflect the 4-for-1 stock split effective August 28, 2026.

Truxton Corporation
Selected Quarterly Financial Data
At Or For The Three Months Ended
(000’s)
(Unaudited)
		September 30, 2026*	June 30, 2026*	September 30, 2025*
Per Common Share Data
Net income attributable to common shareholders, per share:
Basic		$0.68	$0.60	$0.49
Diluted		$0.68	$0.59	$0.49
Book value per common share		$10.62	$10.78	$9.63
Tangible book value per common share		$10.62	$10.78	$9.63
Basic weighted average common shares		11,220,122	11,266,726	11,203,764
Diluted weighted average common shares		11,228,247	11,272,753	11,215,931
Common shares outstanding at period end		11,534,908	11,555,336	11,507,336
Selected Balance Sheet Data
Tangible common equity ratio		9.07%	9.11%	8.44%
Average Loans		$803,068	$803,039	$703,823
Average earning assets (1)		$1,327,804	$1,338,849	$1,279,930
Average total assets		$1,365,948	$1,376,052	$1,309,545
Average shareholders’ equity		$126,897	$122,335	$104,688
Selected Asset Quality Measures
Nonaccrual loans		$84	$87	$97
90+ days past due still accruing		$12	$54	$0
Total nonperforming loans		$96	$141	$97
Total nonperforming assets		$96	$141	$97
Net charge offs (recoveries)		$1	$2	$0
Nonperforming loans to assets		0.01%	0.01%	0.01%
Nonperforming assets to total assets		0.01%	0.01%	0.01%
Nonperforming assets to total loans and other real estate		0.01%	0.02%	0.01%
Allowance for credit losses to total loans		0.92%	0.92%	0.98%
Net charge offs to average loans		0.00%	0.00%	0.00%
Capital Ratios (Bank Subsidiary Only)
Tier 1 leverage		9.66%	9.27%	8.90%
Common equity tier 1		14.54%	14.02%	13.35%
Total risk-based capital		15.44%	14.92%	14.24%
Selected Performance Ratios
Efficiency ratio		48.34%	49.11%	50.63%
Return on average assets		2.28%	2.00%	1.71%
Return on average shareholders’ equity		24.58%	22.54%	21.33%
Return on average tangible common equity		24.58%	22.54%	21.33%
Net interest margin		3.13%	3.10%	2.82%
*The information is preliminary, unaudited and based on company data available at the time of presentation.
(1) Average earning assets is the daily average of earning assets. Earning assets consists of loans, mortgage loans held for sale, federal funds sold, deposits with banks, and investment securities.

Truxton Corporation
Yield Tables
For The Periods Indicated
(000’s)
(Unaudited)
The following table sets forth the amount of our average balances, interest income or interest expense for each category of interest earning assets and interest-bearing liabilities and the average interest rate for interest earning assets and interest-bearing liabilities, net interest spread and net interest margin for the periods indicated below:
		Three Months Ended September 30, 2026*					Three Months Ended June 30, 2026*					Three Months Ended September 30, 2025*
		Average Balances	Rates / Yields (%)	Interest Income / Expense			Average Balances	Rates / Yields (%)	Interest Income / Expense			Average Balances	Rates / Yields (%)	Interest Income / Expense
Earning assets
Loans		$803,068	6.16	$12,460			$803,039	6.04	$12,091			$703,823	6.19	$10,988
Loan fees		$0	0.10	$204			$0	0.13	$255			$0	0.18	$324
Loans, including fees		$803,068	6.26	$12,664			$803,039	6.17	$12,346			$703,823	6.37	$11,312
Taxable securities		$432,504	4.89	$5,291			$436,307	4.95	$5,400			$464,406	4.92	$5,710
Tax-exempt securities		$67,221	5.45	$614			$67,101	5.40	$607			$60,971	5.07	$518
Interest-bearing deposits in other financial institutions		$20,099	3.56	$181			$28,022	3.61	$252			$47,042	4.33	$513
Federal funds sold		$4,912	3.63	$46			$4,380	3.68	$41			$3,688	4.35	$41
Total earning assets		$1,327,804	5.72	$18,796			$1,338,849	5.67	$18,646			$1,279,930	5.70	$18,094
Noninterest earning assets
Allowance for credit losses		($7,751)					($7,944)					($6,749)
Cash and due from financial institutions		$6,656					$5,383					$5,058
Premises and equipment		$2,609					$2,743					$3,094
Accrued interest receivable		$4,577					$4,363					$4,433
Other assets		$46,052					$44,387					$40,883
Unrealized loss on investment securities		($13,999)					($11,729)					($17,104)
Total assets		$1,365,948					$1,376,052					$1,309,545
Interest-bearing liabilities
Interest-bearing demand		$400,561	2.88	$2,904			$384,078	2.82	$2,699			$357,704	3.21	$2,894
Savings and money market		$283,304	2.48	$1,772			$279,119	2.48	$1,729			$261,382	2.74	$1,807
Time deposits – retail		$12,102	3.23	$98			$8,812	3.23	$71			$11,998	3.35	$101
Time deposits – wholesale		$311,638	3.94	$3,094			$356,978	3.85	$3,425			$381,887	4.06	$3,908
Total interest-bearing deposits		$1,007,605	3.10	$7,868			$1,028,987	3.09	$7,924			$1,012,971	3.41	$8,710
Subordinated debentures and other		$0	0.00	$0			$0	0.00	$0			$13,743	5.36	$189
Short-term borrowings		$10,141	2.75	$71			$7,364	1.48	$28			$5,614	4.23	$20
Long-term borrowings		$77,120	3.76	$740			$67,319	3.72	$632			$36,467	4.20	$392
Total borrowed funds		$87,261	3.64	$811			$74,683	3.50	$660			$55,824	4.21	$601
Total interest-bearing liabilities		$1,094,866	3.14	$8,679			$1,103,670	3.12	$8,584			$1,068,795	3.45	$9,311
Net interest rate spread			2.58	$10,117				2.55	$10,062				2.25	$8,783
Non-interest bearing deposits		$139,238					$141,300					$127,953
Other liabilities		$4,947					$8,747					$8,109
Shareholders’ equity		$126,897					$122,335					$104,688
Total liabilities and shareholders’ equity		$1,365,948					$1,376,052					$1,309,545
Cost of funds			2.79					2.76					3.08
Net interest margin			3.13					3.10					2.82
*The information is preliminary, unaudited and based on company data available at the time of presentation.
Yield Table Assumptions – Average loan balances are inclusive of nonperforming loans. Net interest spread is calculated as the yields realized on interest-bearing assets less the rates paid on interest-bearing liabilities. Changes in net interest income are attributed to either changes in average balances (volume change) or changes in average rates (rate change) for earning assets and sources of funds on which interest is received or paid. Volume change is calculated as change in volume times the previous rate while rate change is change in rate times the previous volume. Changes not due solely to volume or rate changes are allocated to volume change and rate change in proportion to the relationship of the absolute dollar amounts of the change in each category.

Truxton Corporation Yield Tables For The Periods Indicated (000’s) (Unaudited)
The following table sets forth the amount of our average balances, interest income or interest expense for each category of interest earning assets and interest-bearing liabilities and the average interest rate for interest earning assets and interest-bearing liabilities, net interest spread and net interest margin for the periods indicated below:
		Nine Months Ended				Nine Months Ended
		September 30, 2026*				September 30, 2025*
		Average Balances	Rates / Yields (%)	Interest Income / Expense		Average Balances	Rates / Yields (%)	Interest Income / Expense
Earning assets
Loans		$809,801	6.07	$36,738		$695,162	6.13	$31,705
Loan fees		$0	0.12	$725		$0	0.13	$867
Loans, including fees		$809,801	6.19	$37,463		$695,162	6.26	$32,572
Taxable securities		$436,437	4.95	$16,218		$394,960	4.86	$14,389
Tax-exempt securities		$66,707	5.42	$1,816		$47,251	4.54	$1,077
Interest-bearing deposits in other financial institutions		$22,890	3.72	$637		$35,788	4.33	$1,159
Federal funds sold		$5,189	3.65	$143		$3,128	4.18	$99
Total earning assets		$1,341,024	5.69	$56,277		$1,176,289	5.66	$49,296
Noninterest earning assets
Allowance for credit losses		($7,943)				($6,691)
Cash and due from financial institutions		$6,231				$9,132
Premises and equipment		$2,740				$3,157
Accrued interest receivable		$4,461				$4,033
Other assets		$43,001				$50,825
Unrealized loss on investment securities		($11,466)				($17,598)
Total assets		$1,378,048				$1,219,147
Interest-bearing liabilities
Interest-bearing demand		$386,458	2.83	$8,169		$338,396	3.09	$7,821
Savings and money market		$272,986	2.47	$5,036		$249,101	2.70	$5,033
Time deposits – retail		$10,130	3.20	$242		$12,547	3.38	$317
Time deposits – wholesale		$363,330	3.79	$10,286		$314,845	4.19	$9,857
Total interest-bearing deposits		$1,032,904	3.07	$23,733		$914,889	3.37	$23,028
Subordinated debentures and other		$0	0.00	$0		$14,319	5.20	$565
Short-term borrowings		$7,601	1.88	$108		$8,727	4.31	$188
Long-term borrowings		$64,839	3.74	$1,838		$32,525	4.15	$1,024
Total borrowed funds		$72,440	3.54	$1,946		$55,571	4.22	$1,777
Total interest-bearing liabilities		$1,105,344	3.10	$25,679		$970,460	3.41	$24,805
Net interest rate spread			2.59	$30,598			2.24	$24,491
Non-interest bearing deposits		$142,661				$130,989
Other liabilities		$7,104				$5,552
Shareholders’ equity		$122,939				$112,146
Total liabilities and shareholders’ equity		$1,378,048				$1,219,147
Cost of funds			2.75				3.01
Net interest margin			3.14				2.84
*The information is preliminary, unaudited and based on company data available at the time of presentation.
Yield Table Assumptions – Average loan balances are inclusive of nonperforming loans. Net interest spread is calculated as the yields realized on interest-bearing assets less the rates paid on interest-bearing liabilities. Changes in net interest income are attributed to either changes in average balances (volume change) or changes in average rates (rate change) for earning assets and sources of funds on which interest is received or paid. Volume change is calculated as change in volume times the previous rate while rate change is change in rate times the previous volume. Changes not due solely to volume or rate changes are allocated to volume change and rate change in proportion to the relationship of the absolute dollar amounts of the change in each category.

NEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) — Today Roivant Social Ventures (RSV) announced it is joining efforts with No Patient Left Behind (NPLB) to improve drug affordability and access while supporting ongoing medical innovation, through a six-figure legacy donation.

RSV is a 501(c)3 public charity and social impact organization that partners with innovative companies, institutes, and organizations to promote systemic, sustained improvements to the way health care is accessed and delivered. The organization launched with the vision of a world where every person is born with the right and ability to access medicine and medical care, regardless of their geographic location, wealth, or insurance status. In striving for this goal, RSV spent the last six years building out programing to increase access to therapeutics for underserved people, while working to embed these principles throughout the biotechnology and healthcare industries.

In this next chapter, RSV closes out its own institutional work, while putting full support behind NPLB to enhance organizational mission fulfillment, operational efficiency, and community impact. 

Lindsay Androksi, RSV Founder and Board President, shared, “I am immensely proud of RSV’s work incubating and investing in early-stage companies and launching and expanding educational and fellowship opportunities for future equity-minded industry leaders. We also co-founded groups working to bring new therapies to underserved patient populations, such as the Global Gene Therapy Initiative and the Catalyzing Access to Research and Equity in Representation Group, and are excited to see those organizations continue their important work.

I am grateful to Roivant Sciences for enthusiastically supporting the launch of Roivant Social Ventures six years ago and our projects since that time. I can think of no better organization to carry on our legacy than NPLB.”

“Roivant Social Ventures has opened doors for people who need help accessing medicines,” said Priscilla VanderVeer, Executive Director of No Patient Left Behind. “We’re honored by this donation, and will continue their legacy as we work to improve affordability while preserving the innovation ecosystem we all rely on.” 

About No Patient Left Behind (NPLB)

NPLB is a network of biotechnology innovators, investors, economists, healthcare professionals, and patients working together to support solutions that improve affordability while preserving the innovation ecosystem we all rely on. NPLB’s work educates stakeholders and policymakers about balanced policy solutions that enable every patient to afford the drugs prescribed by their doctor at low or no out-of-pocket cost — while also preserving the incentives for investment that spur the development of new, life-saving treatments.

NPLB’s Goals are to:

• Eliminate out-of-pocket costs
• Preserve and expedite development of the cures we still need
• Ensure drugs go generic on time
• Inspire all countries to appreciate the value of medicines and contribute their fair share to incentivizing innovation

You can learn more about NPLB’s work, including their free Biotech Fellowship program, through visiting their website: https://www.nopatientleftbehind.org/

RSV would like to extend a heart-felt thank you to all of those who have supported the organization’s important work in healthcare equity and access over the past six years.

Contact:
Amanda Waldhauser, Roivant Social Ventures’ Executive Director
amanda.waldhauser@roivant.com

ENGLEWOOD, Colo., Oct. 29, 2026 (GLOBE NEWSWIRE) — Gevo, Inc. (NASDAQ: GEVO) today announced it will host a conference call at 4:30 p.m. ET Tuesday, November 10 to report its financial results for the third quarter ended September 30.

To participate in the live call, please register through the following event weblink: https://registrations.events/direct/Q4I39798VIPxW5nsSJ16f5S3f

To listen to the conference call (audio only, non-participating), please register through the following event weblink: https://events.q4inc.com/attendee/990337405

A webcast replay will be available after the conference call ends on November 10. The archived webcast will be available in the Investor Relations section of Gevo’s website at investors.gevo.com.

About Gevo
Gevo is a next-generation diversified energy company committed to fueling America’s future with cost-effective, drop-in fuels that contribute to energy security, abate carbon, and strengthen rural communities to drive economic growth. Gevo’s innovative technology can be used to make a variety of renewable products, including sustainable aviation fuel (SAF), motor fuels, chemicals, and other materials that provide U.S.-made solutions. Gevo’s business model includes developing, financing, and operating production facilities that create jobs and revitalize communities. Gevo owns and operates an ethanol plant with an adjacent carbon capture and storage (CCS) facility and Class VI carbon-storage well. Gevo also owns and operates one of the largest dairy-based renewable natural gas (RNG) facilities in the United States, turning by-products into clean, reliable energy. Additionally, Gevo developed the world’s first production facility for specialty alcohol-to-jet (ATJ) fuels and chemicals operating since 2012. Gevo is currently developing the world’s first large-scale ATJ facility to be co-located at our North Dakota site. Gevo’s market-driven “pay-for-performance” approach regarding carbon and other sustainability attributes helps deliver value to our local economies. Through its Verity subsidiary, Gevo provides transparency, accountability, and efficiency in tracking, measuring, and verifying various attributes throughout the supply chain. By strengthening rural economies, Gevo is working to secure a self-sufficient future and to make sure value is brought to the market.

For more information, see www.gevo.com.

MEDIA CONTACT
PR@gevo.com 

IR CONTACT
IR@gevo.com 

REDWOOD CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the third quarter of 2026 on Thursday, November 12, 2026, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update.

Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the call will be available for 48 hours by dialing 877-660-6853 (domestic) or 201-612-7415 (international), access ID #13726635.

About Codexis

Codexis® is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis® manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.

For More Information
Investor Contact
Georgia Erbez
(650) 421-8100
ir@codexis.com

NEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) — Verizon Communications Inc. (“Verizon”) (NYSE, Nasdaq: VZ) today announced the commencement of five separate offers to purchase for cash up to $500 million aggregate purchase price of the outstanding series of its notes listed in the table below (collectively, the “Notes” and such tender offers, the “Offers”), on the terms and subject to the conditions set forth in the Offer to Purchase dated October 29, 2026 (the “Offer to Purchase”). 

Verizon is offering to purchase validly tendered Notes using a “waterfall” methodology under which the Notes will be accepted in the order of their Acceptance Priority Levels, subject to the Waterfall Cap (as defined below) and, in the case of the 3.000% Notes due November 20, 2060, the 3.700% Notes due March 22, 2061 and the 2.650% Notes due November 20, 2040 (collectively, the “Sub Cap Notes”), the Sub Cap (as defined below). The Offers are subject to the terms and conditions described in the Offer to Purchase, including (i) the Acceptance Priority Procedures (as described below), (ii) a $155 million cap (the “Sub Cap”) on the total cash Verizon pays to purchase Sub Cap Notes validly tendered under the Offers (excluding the applicable Accrued Coupon Payment (as defined below)) and (iii) a $500 million cap (the “Waterfall Cap”) on the total cash Verizon pays to purchase all Notes validly tendered under the Offers (excluding the applicable Accrued Coupon Payment and including cash paid to purchase any Sub Cap Notes).

On the terms and subject to the conditions set forth in the Offer to Purchase, Verizon is offering to purchase the following outstanding notes for the consideration described below. Terms not otherwise defined are defined in the Offer to Purchase.

Acceptance Priority Level(1)	Title of Security	CUSIP/ISIN Number	Principal Amount Outstanding		Sub Cap(2)		Reference  U.S. Treasury Security(3)		Bloomberg Reference Page	Fixed Spread (Basis Points)(3)
1	3.000% Notes due November 20, 2060	92343VFV1 / US92343VFV18	$1,864,262,000		$155,000,000		5.000% UST due 5/15/2056		FIT1	+110
2	3.700% Notes due March 22, 2061	92343VGC2 / US92343VGC28	$2,670,732,000				5.000% UST due 5/15/2056		FIT1	+115
3	2.650% Notes due November 20, 2040	92343VFT6 / US92343VFT61	$1,948,887,000				4.625% UST due 8/15/2036		FIT1	+130
4	2.100% Notes due March 22, 2028	92343VGH1 / US92343VGH15	$917,789,000		Not Applicable		3.875% UST due 3/15/2028		FIT4	+25
5	3.150% Notes due March 22, 2030	92343VFE9 / US92343VFE92	$1,140,001,000		Not Applicable		5.000% UST due 9/30/2031		FIT1	+50

(1)	Subject to the satisfaction or waiver of the conditions of the Offers described in the Offer to Purchase, if the aggregate total consideration for each $1,000 principal amount of each series of Notes validly tendered at or prior to the Expiration Date, and not validly withdrawn, and accepted by Verizon pursuant to the Offers (the “Total Consideration”) exceeds the Waterfall Cap, Verizon will accept Notes for purchase in the order of their respective Acceptance Priority Level specified in the table above (each, an “Acceptance Priority Level,” with 1 being the highest Acceptance Priority Level and 5 being the lowest Acceptance Priority Level), subject, in the case of the Sub Cap Notes, to the Sub Cap. It is possible that a series of Notes with a particular Acceptance Priority Level will not be accepted for purchase or will be accepted only on a prorated basis.
(2)	The Sub Cap limits the aggregate Total Consideration payable for the Sub Cap Notes purchased pursuant to the Offers, collectively, to $155,000,000. Verizon reserves the right, but is under no obligation, to waive or increase the Sub Cap at any time, subject to applicable law.
(3)	The Total Consideration for each series of Notes validly tendered will be determined in accordance with standard market practice, as described in the Offer to Purchase, to result in a price as of the applicable Settlement Date (as defined below) that equates to a yield to the applicable maturity date (or, if the price so determined would be greater than $1,000 per $1,000 principal amount of Notes, the applicable par call date) in accordance with the formula set forth in Annex A to the Offer to Purchase, for the applicable series of Notes, equal to the sum of (i) the yield corresponding to the bid side price of the applicable Reference U.S. Treasury Security specified in the table above for such series of Notes as of the Price Determination Date (as defined below) quoted on the Bloomberg reference page “FIT1” or “FIT4,” as specified in the table above for such series of Notes, plus (ii) the applicable “Fixed Spread” specified in the table above for such series of Notes. The Total Consideration does not include the applicable Accrued Coupon Payment, which will be payable in cash in addition to the applicable Total Consideration.

The Offers will each expire at 5:00 p.m. (New York City time) on November 4, 2026, unless extended or earlier terminated by Verizon (such date and time with respect to an Offer, as the same may be extended with respect to such Offer, the “Expiration Date”). All Holders (as defined in the Offer to Purchase) whose Notes are accepted in an Offer will receive a cash payment equal to accrued and unpaid interest on such Notes to, but excluding, the Settlement Date (as defined below) (the “Accrued Coupon Payment”) in addition to their Total Consideration. Notes may be validly withdrawn at any time at or prior to 5:00 p.m. (New York City time) on November 4, 2026, unless extended or earlier terminated with respect to any Offer, but not thereafter. Upon the terms and subject to the conditions set forth in the Offer to Purchase, Holders who validly tender, and do not validly withdraw, Notes at or prior to the Expiration Date, and whose Notes are accepted for purchase by Verizon, will receive the applicable Total Consideration per $1,000 principal amount of such Notes. Subject to applicable law and limitations described in the Offer to Purchase, Verizon expressly reserves the right to amend, extend or, to the extent the conditions described in the Offer to Purchase are not satisfied or waived, terminate any of the Offers at any time at or prior to the Expiration Date.

Subject to the satisfaction or waiver of the conditions of the Offers, the “Acceptance Priority Procedures” with respect to the Offers will operate as follows:

• if the aggregate Total Consideration for all Notes validly tendered at or prior to the Expiration Date does not exceed the Waterfall Cap, and the aggregate Total Consideration for all Sub Cap Notes validly tendered at or prior to the Expiration Date does not exceed the Sub Cap, then Verizon will accept all such Notes;
• if the aggregate Total Consideration for all Sub Cap Notes validly tendered at or prior to the Expiration Date exceeds the Sub Cap, and the aggregate Total Consideration for all Notes validly tendered at or prior to the Expiration Date does not exceed the Waterfall Cap (subject to Verizon’s right to waive or increase the Sub Cap at its discretion, subject to applicable law), then Verizon will first, accept for purchase all validly tendered Sub Cap Notes of each series starting at the highest Acceptance Priority Level (level 1) and moving sequentially to Sub Cap Notes of each series having a lower Acceptance Priority Level (the lowest of which is level 3), until the aggregate Total Consideration for all validly tendered Sub Cap Notes of the applicable series, together with the aggregate Total Consideration for all Sub Cap Notes accepted for purchase from series with higher Acceptance Priority Levels, is as close as possible to, but does not exceed, the Sub Cap; second, to the extent the Sub Cap would otherwise be exceeded, accept on a prorated basis validly tendered Sub Cap Notes of the series with the next lower Acceptance Priority Level, and Verizon will not accept for purchase any Sub Cap Notes of a series with an Acceptance Priority Level below the prorated series; and third, accept for purchase all validly tendered Notes of each series starting with Acceptance Priority Levels following the Sub Cap Notes (level 4 and level 5); and
• if the aggregate Total Consideration for all Notes validly tendered at or prior to the Expiration Date exceeds the Waterfall Cap and the aggregate Total Consideration for all Sub Cap Notes so tendered exceeds the Sub Cap (in each case, subject to Verizon’s right to waive or increase the Waterfall Cap or the Sub Cap at its discretion, subject to applicable law), then subject to the limitations imposed by the Waterfall Cap described below, Verizon will first, accept for purchase all validly tendered Sub Cap Notes of each series starting at the highest Acceptance Priority Level (level 1) and moving sequentially to Sub Cap Notes of each series having a lower Acceptance Priority Level (the lowest of which is level 3), until the aggregate Total Consideration for all validly tendered Sub Cap Notes of the applicable series, together with the aggregate Total Consideration for all Sub Cap Notes accepted for purchase from series with higher Acceptance Priority Levels, is as close as possible to, but does not exceed, the Sub Cap; second, to the extent the Sub Cap would otherwise be exceeded, accept on a prorated basis validly tendered Sub Cap Notes of the series with the next lower Acceptance Priority Level, and Verizon will not accept for purchase any Sub Cap Notes of a series with an Acceptance Priority Level below the prorated series; third, for the Waterfall Cap, subject to the limitations imposed by the Sub Cap above, accept for purchase validly tendered Notes of each series starting at the highest Acceptance Priority Level (level 1) and moving sequentially to the series of Notes having the lowest Acceptance Priority Level (level 5), until the aggregate Total Consideration for all validly tendered Notes of the applicable series, together with the aggregate Total Consideration for all Notes (including Sub Cap Notes) accepted for purchase from series with higher Acceptance Priority Levels, is as close as possible to, but does not exceed, the Waterfall Cap; and fourth, accept on a prorated basis (following the procedures described in the Offer to Purchase) validly tendered Notes of the series with the next lower Acceptance Priority Level, and Verizon will not accept for purchase any Notes of a series with an Acceptance Priority Level below the prorated series. For the avoidance of doubt, if the aggregate Total Consideration for all Notes validly tendered at or prior to the Expiration Date exceeds the Waterfall Cap but the aggregate Total Consideration for all Sub Cap Notes so tendered does not exceed the Sub Cap (in each case, subject to Verizon’s right to waive or increase the Waterfall Cap or the Sub Cap at its discretion, subject to applicable law), then Verizon will first accept for purchase validly tendered Notes of each series starting with the Acceptance Priority Level 1 and moving sequentially to the series of Notes having the lowest Acceptance Priority Level (level 5), until the aggregate Total Consideration for all validly tendered Notes of the applicable series, together with the aggregate Total Consideration for all Notes (including Sub Cap Notes) accepted for purchase from series with higher Acceptance Priority Levels, is as close as possible to, but does not exceed, the Waterfall Cap; and second, accept on a prorated basis validly tendered Notes of the series with the next lower Acceptance Priority Level, and Verizon will not accept for purchase any Notes of a series with an Acceptance Priority Level below the prorated series.

The “Settlement Date,” if any, is the date on which Verizon will settle all Notes of a series validly tendered and accepted for purchase, subject to all conditions having been satisfied or waived by Verizon. The Settlement Date is expected to be the third business day following the applicable Expiration Date (November 9, 2026), unless the Expiration Date is extended with respect to any Offer.

The applicable Total Consideration payable by Verizon for each $1,000 principal amount of each series of Notes validly tendered at or prior to the Expiration Date, and not validly withdrawn, and accepted by Verizon will be paid in cash on the Settlement Date.

Promptly after 2:00 p.m. (New York City time) on November 4, 2026, unless extended with respect to an Offer (such date and time with respect to an Offer, as the same may be extended with respect to such Offer, the “Price Determination Date”), Verizon will issue a press release announcing, among other things, the Offer Yield (as defined in the Offer to Purchase) and the Total Consideration for each series of Notes. If the Expiration Date with respect to an Offer is extended by more than 24 hours, the applicable Price Determination Date will be extended to 2:00 p.m. (New York City time) on the same day as the new Expiration Date.

Promptly after the Expiration Date, and in any event by 10:00 a.m. (New York City time) on the next business day, Verizon will announce the aggregate principal amount of Notes accepted in each Offer and any applicable proration factor.

Verizon has retained Barclays Capital Inc. and Scotia Capital (USA) Inc. to act as dealer managers for the Offers. Questions regarding terms and conditions of the Offers should be directed to Barclays Capital Inc. at us.lm@barclays.com or (212) 528-7581 (collect) or Scotia Capital (USA) Inc. at LM@scotiabank.com or (212) 225-5559 (collect). Global Bondholder Services Corporation will act as the Tender Agent and the Information Agent for the Offers. Questions or requests for assistance related to the Offers or for additional copies of the Offer to Purchase may be directed to Global Bondholder Services Corporation at (855) 654-2015 (toll free) or (212) 430-3774 (collect). Copies of the Offer to Purchase are also available at the following web address: https://www.gbsc-usa.com/verizon. You may also contact your broker, dealer, commercial bank, trust company or other nominee for assistance concerning the Offers.

If Verizon terminates any Offer with respect to one or more series of Notes, it will give prompt notice to the Tender Agent and Information Agent, and all Notes tendered pursuant to such terminated Offer will be returned promptly to the tendering Holders thereof. With effect from such termination, any Notes blocked in The Depository Trust Company (“DTC”) will be released.

Holders are advised to check with any bank, securities broker or other intermediary through which they hold Notes as to when such intermediary would need to receive instructions from a beneficial owner in order for that Holder to be able to participate in, or (in the circumstances in which withdrawal is permitted) withdraw their instruction to participate in, the Offers before the deadlines specified herein and in the Offer to Purchase. The deadlines set by any such intermediary and DTC for the submission and withdrawal of tender instructions may be earlier than the relevant deadlines specified herein and in the Offer to Purchase.

This announcement is for informational purposes only. This announcement is not an offer to purchase or a solicitation of an offer to purchase any Notes. The Offers are being made solely pursuant to the Offer to Purchase and related documents. The Offers are not being made to Holders of Notes in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction. In any jurisdiction in which the securities laws or blue sky laws require the Offers to be made by a licensed broker or dealer, the Offers will be deemed to be made on behalf of Verizon by the dealer managers or one or more registered brokers or dealers that are licensed under the laws of such jurisdiction.

This communication and any other documents or materials relating to the Offers have not been approved by an authorized person for the purposes of Section 21 of the Financial Services and Markets Act 2000, as amended (the “FSMA”). Accordingly, this announcement is not being distributed to, and must not be passed on to, persons within the United Kingdom save in circumstances where section 21(1) of the FSMA does not apply. Accordingly, this communication is only addressed to and directed at (i) persons who are outside the United Kingdom, or (ii) persons falling within the definition of investment professionals (as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Financial Promotion Order”)), or (iii) within Article 43 of the Financial Promotion Order, or (iv) high net worth companies and other persons to whom it may lawfully be communicated falling within Article 49(2)(a) to (d) of the Financial Promotion Order (such persons together being “relevant persons”). This announcement is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons.

This communication and any other documents or materials relating to the Offers are only addressed to and directed at persons in member states of the European Economic Area (the “EEA”), who are “Qualified Investors” within the meaning of Article 2(1)(e) of Regulation (EU) 2017/1129. The Offers are only available to Qualified Investors. None of the information in any document or material relating to the Offers should be acted upon or relied upon in any member state of the EEA by persons who are not Qualified Investors.

Cautionary Statement Regarding Forward-Looking Statements

In this communication Verizon has made forward-looking statements, including regarding the conduct and completion of the Offers. These forward-looking statements are not historical facts, but only predictions and generally can be identified by use of statements that include phrases such as “will,” “may,” “should,” “continue,” “anticipate,” “believe,” “expect,” “plan,” “appear,” “project,” “estimate,” “intend,” “target,” “forecast,” or other words or phrases of similar import. Similarly, statements that describe our objectives, plans or goals also are forward-looking statements. These forward-looking statements are subject to risks and uncertainties which could cause actual results to differ materially from those currently anticipated, including those discussed in the Offer to Purchase under the heading “Risk Factors” and under similar headings in other documents that are incorporated by reference into the Offer to Purchase. Holders are urged to consider these risks and uncertainties carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements included in this press release are made only as of the date of this press release, and Verizon undertakes no obligation to update publicly these forward-looking statements to reflect new information, future events or otherwise. In light of these risks, uncertainties and assumptions, the forward-looking events might or might not occur. Verizon cannot assure you that projected results or events will be achieved.

This announcement was originally published by Verizon. Read the original press release.

Media contact:
Katie Magnotta
201-602-9235
katie.magnotta@verizon.com 

Enhancements to workforce technology platform enable faster, better-informed talent decisions

Facts at a Glance:

• Sevayo is now powered by an AI assistant that guides hiring managers through workforce decisions.
• New voice-enabled intake allows hiring managers to start requisitions quickly and easily.
• Market rates and benchmark data are available within the platform at the point of requisition.

TROY, Mich., Oct. 29, 2026 (GLOBE NEWSWIRE) — Kelly® (Nasdaq: KELYA, KELYB), a global workforce strategy and solutions provider, has introduced new capabilities in Sevayo®, its proprietary workforce technology platform that offers employers greater visibility and actionable insights across every worker type and channel. The enhancements include a generative AI assistant, voice-enabled requisition intake, and live market data, helping hiring managers make more informed talent decisions from the start of the requisition process.

“Workforce outcomes are largely determined at the requisition, when a hiring manager decides what to buy, from whom, and at what rate,” said Alan Stukalsky, chief product and technology officer at Kelly. “Sevayo’s AI-powered capabilities give hiring managers the guidance, data, and support they need in that moment, so the right decision is also the easiest one.”

Sevayo connects clients’ existing systems with external talent channels, including contingent staffing, services procurement, freelance talent, and direct sourcing, on one unified platform. It brings workforce information together across connected vendor management (VMS), applicant tracking (ATS), and human resources information systems (HRIS), helping organizations build a complete view of talent, activity, and spend.

New capabilities include:

• Generative AI assistant: Hiring managers can ask questions in natural language and receive guidance as they assess requisition needs and workforce options.
• Voice-enabled intake: Hiring managers can begin a requisition simply by speaking, making the intake process faster and more accessible.
• Live market data: Benchmark and rate information is built into the requisition workflow, giving managers market context as they make hiring decisions.

Sevayo is designed to route each talent request to the appropriate channel and apply governance and compliance controls before a requisition is placed. Its unified data environment aggregates and enriches information across talent types, sources, systems, and spend categories to give clients a single source of workforce insight.

The platform brings practical AI and decision support into workforce planning and operations. Talent market predictions and scenario modeling help organizations anticipate talent needs and weigh options based on cost, compliance, and speed. Real-time labor-market intelligence can inform pay rates, skills-gap planning, and competitive positioning.

Sevayo further aligns clients’ Managed Service Provider (MSP) and Recruitment Process Outsourcing (RPO) data to support integrated workforce programs. It streamlines portfolio-level performance insights across both contingent and full-time hiring, while business-ready dashboards make supplier activity and workforce spend more transparent. That cohesive view is changing how clients plan their workforce.

Kelly made the enhancements after bringing its Helix, Helix UX, and Sevayo Insights tools together under the Sevayo® name. The combined platform is the foundation for future agentic automation across Kelly programs as the company continues to build the infrastructure and expand use cases over time.

“Clients are asking for unified, strategic solutions that cut across their entire workforce,” Stukalsky said. “Sevayo is the foundation of our workforce programs, so intelligence is built into everything we deliver, not bolted on afterward.”

About Kelly^®

At Kelly® (Nasdaq: KELYA, KELYB), we don’t just understand the future of work, we’re defining it. For over 80 years, we’ve sourced specialized talent, built agile workforces, and shaped growth strategies for employers around the world. Today, our recruiting, outsourcing, and consulting services provide the talent and solutions organizations need to move faster and grow smarter. We deliver meaningful impact by connecting people to work that enriches their lives, and companies to people who drive innovation and growth. Each year, we place more than 375,000 job seekers in new roles spanning science, engineering, technology, telecom, education, manufacturing, and more.

Media Contact

Christian Taske

248-561-8823

christian.taske@kellyservices.com

This press release was published by a CLEAR® Verified individual.

Two-year cooperation pairs local institutional outreach with Formind Global’s platform contracting and support

KUALA LUMPUR, Malaysia, Oct. 29, 2026 (GLOBE NEWSWIRE) — Ruanyun Edai Technology Inc. (NASDAQ: RYET) (“Ruanyun” or the “Company”) announced that its Malaysian subsidiary, Formind Global Holdings Sdn. Bhd. (“Formind Global”), has entered into a marketing cooperation agreement with Fangtu, a Taiwan-based company that will lead local promotion and institutional customer development for the HanLink Chinese learning platform in Taiwan.

The two-year cooperation covers local market promotion, customer development and school procurement referrals. Fangtu will engage schools, universities and Chinese-language centres and assist with demonstrations, pilots, teacher training and customer feedback. Formind Global will provide the platform, demonstration environment and technical and sales materials, and undertake commercial contracting and service obligations under individual school agreements.

HanLink combines digital Chinese-language courses with AI-assisted interaction, practice and learning assessment. Its tools are designed to give students more opportunities to practise and help institutions extend teaching support beyond scheduled lessons. The parties intend to supplement teacher-led instruction, with individual school implementations agreed separately.

“For a language-learning platform, local institutional relationships and support are as important as the technology. We want HanLink to fit into the way institutions teach, while giving students more opportunities to practise between lessons. Working with Fangtu gives us a local partner to develop that opportunity in Taiwan, with Formind Global connecting customer engagement to the platform and its delivery.”

Maggie Fu, Chief Executive Officer, Ruanyun Edai Technology Inc.

Local Market Development and Direct School Contracting
The cooperation is non-exclusive, and either party may terminate it on 30 days’ written notice. Fangtu will be Formind Global’s preferred marketing partner in Taiwan for the first 12 months; exclusivity would require a separate written agreement. Schools that proceed with procurement will contract with and pay Formind Global directly.

The agreement sets a standard annual platform fee of US$30,000 per school, with a fixed NT$980,000 alternative for contracts denominated in New Taiwan dollars. Each school’s quotation and executed contract will specify the selected currency, price, licensed scope and service arrangements. Fangtu will be eligible for a 20% commission on the net contract amount of school agreements arising from registered opportunities accepted by Formind Global, with commission payments tied to the corresponding school payments collected.

The marketing agreement does not itself commit any school to purchase HanLink or establish minimum sales. Any revenue contribution will depend on school contracts, delivery of the relevant services, collectability and applicable accounting requirements.

Building HanLink’s International Business
The Taiwan agreement adds another local market-development arrangement to HanLink’s international activities. HanLink’s previously announced Saudi activities include school pilot work and university cooperation, followed by commercial school contracting through Link Door Smart Company, the Company’s separately owned strategic associate. In the United States, Ruanyun announced a HanLink pilot with the Center on Chinese Education at Teachers College, Columbia University, supported by a Company grant to evaluate AI-assisted learning.

Through its Formind Group strategy, the Company is seeking to connect AI applications and education with institutional partnerships, implementation and continuing support. The Taiwan cooperation is intended to apply that approach to Chinese-language learning through local customer engagement and direct platform procurement.

About Ruanyun Edai Technology Inc.
Ruanyun Edai Technology Inc. is an AI-driven education technology company focused on intelligent content recognition, automated assessment and next-generation learning systems. The Company has historically developed and provided AI-enabled teaching, learning and assessment solutions, including smart homework, smart examination and digital education services, and since September 2025 has provided campus operations and student-life services through its Smart Campus Services business. The Company is presenting its group businesses under the Formind Group identity as part of its broader strategy to expand AI education, language learning, institutional education support and global technology initiatives. Additional information about Formind Group is available at www.formind.group. Information on that website is not part of this press release.

Forward-Looking Statements
This press release contains forward‑looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 and applicable securities laws. All statements other than statements of historical fact are forward‑looking statements. Forward‑looking statements may be identified by words such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “goal,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar expressions.

These statements include, among others, statements regarding the anticipated benefits and implementation of the Fangtu cooperation; HanLink’s promotion, adoption and commercialization in Taiwan; school procurement, pricing, commissions, collections and any revenue contribution; potential pilots, training, localization and technical support; AI-assisted learning benefits; and the Company’s international education and Formind strategy.

Forward-looking statements are based on current expectations, estimates and assumptions and involve risks and uncertainties that could cause actual results to differ materially. Relevant risks include the parties’ ability to develop customer opportunities and perform their obligations; school procurement decisions and implementation requirements; the absence of committed school purchases or minimum sales; competition and customer adoption; platform performance, AI response quality and educational suitability; licensing, intellectual-property and data-protection requirements; cross-border operations and regulatory compliance; partner performance; collection of customer payments; and revenue recognition and other accounting requirements. The cooperation agreement does not assure customer contracts, successful market entry or any particular financial result.

Forward-looking statements speak only as of the date of this release. Additional risks are described in the Company’s reports filed with or furnished to the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 20-F. The Company undertakes no obligation to update any forward-looking statement except as required by law.

Investor Relations and Corporate Communications
FSR Capital, a FSR Group Company
Email: ir@fsr.group